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ABSTRACT – Background: Gallbladder carcinoma presents a dismal prognosis. Choice treatment 
is surgical resection that is associated a high levels of both morbidity and mortality. Best 
knowledgement of prognostic factors may result a better selection of patients either for 
surgical or multimodal treatment. Aim: To evaluate tecidual immunoexpression of P53, 
E-cadherin, Cox-2, and EGFR proteins and to correlate these findings with resected gallbladder 
adenocarcinoma survival. Methods: Clinical, laboratorial, surgical, and anatomopathological 
reports of a series of gallbladder adenocarcinoma patients were collected by individualized 
questionary. Total sample was 42 patients. Median of age was 72 years (35-87). There were 
seven men and 35 women. Lesion distribuition in according TNM state was the following: 
T1 (n=2), T2 (n=5), T3 (n=31), T4 (n=4). Twenty-three patients underwent radical resection 
(R0), while 19 palliative surgery (R1-R2). A block of tissue microarray with neoplasic tissue of 
each patient was confected. It was performed evaluation of P53, E-Caderine, COX-2, and EGFR 
proteins imunoexpression. These findings were correlated with overall survival. Results: Five-
year survival was 28%. The median of global survival was eight months. Only immunoexpression 
of EGFR protein was considered independent variable at multivariated analysis. Conclusion: 
Final prognosis was influenced by over-expression of EGFR protein in tumoral tissue.
RESUMO – Racional: O carcinoma de vesícula biliar apresenta mau prognóstico. O tratamento 
de escolha é a ressecção cirúrgica que está associado à alta morbimortalidade. O melhor 
conhecimento de fatores prognósticos pode resultar em melhor seleção dos doentes para o 
tratamento cirúrgico e multimodal. Objetivos: Avaliar a imunoexpressão tecidual das proteínas 
P53, E-caderina, Cox-2 e EGFR e correlacionar com a sobrevida do adenocarcinoma de vesícula 
biliar ressecado.  Método:  Os dados clínicos, laboratoriais, cirúrgicos e anatomopatológicos 
de uma série de doentes operados por adenocarcinoma de vesicula biliar foram coletados. 
A casuística total foi de 42 doentes. A mediana de idade foi de 72 anos (35-87). Foram sete 
homens e 35 mulheres. A distribuição da lesão de acordo com TNM  foi a seguinte: T1 (n=2), 
T2 (n=5), T3 (n=31), T4 (n=4). Vinte três doentes realizaram ressecção radical (R0) enquanto 
19 operação paliativa (R1-R2). Um bloco de tissue microarray foi confeccionado com tecido 
neoplásico de cada doente. para avaliação da imunoexpressão das proteínas P53, E-Caderina, 
COX-2 e EGFR. Esses achados foram correlacionados com prognóstico final dos doentes. 
Resultados: A sobrevida estimada em cinco anos foi de 28%.  A mediana de sobrevida 
global foi de oito meses. Apenas a imunoexpressão da proteína EGFR foi considerada variável 
independente no prognóstico dos doentes. Conclusão: Pior prognóstico teve relação com a 
imunoexpressão aumentada da proteína EGFR no tecido tumoral.
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INTRODUCTION
Gallbladder carcinoma is the seventh commonest type of cancer of the digestive tract22. The curative treatment used has been surgical resection and, although early tumors may be treated by means of 
simple cholecystectomy, the great majority of the cases are still composed of 
advanced cases, in which hepatectomy and regional lymphadenectomy become 
essential in order to increase survival or even achieve a cure7,18. Although 
improvement of the surgical results has been observed over the last few decades, 
the specific postoperative mortality due to gallbladder carcinoma has remained 
relatively high, in comparison with other forms of gastrointestinal neoplasia18. 
Since this is a disease of elderly people who present with multiple associated 
diseases, high postoperative mortality is observed even today20. 
Better knowledge of its prognostic factors and tumor biology seems to 
be pertinent, given that this may translate into better selection of patients who 
would benefit from surgical treatment that is more aggressive. In this manner, 
patients might be spared unnecessary risks and expenditure, and screening for 
their multimodal treatment might be aided. Several prognostic factors have 
been studied and, among these, the most important ones have been clinical-
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demographic, laboratory, surgical and histopathological 
factors7,18,20,29. 
In a previous study by the present authors20, 
some of these factors were identified; however, the 
immunoexpression of tissue proteins in tumor tissue was 
not studied. In the form of “biomarkers”, these proteins 
might further expand the spectrum of knowledge of 
their prognostic factors and, moreover, might contribute 
in some way towards studies on specific drugs with the 
capacity to act on certain receptors. In relation to the 
prognosis for gallbladder carcinoma, little has been 
published recently on the prognostic implications of the 
proteins P531,2,9,23,25, E-cadherin (E-CD)11,24, cyclooxygenase 
2 (COX-2)10,14 and epidermal growth factor receptor 
(EGFR)4,6,8,26.  
The aims of the present study were to evaluate the 
tissue expression of the proteins P53, E-CD, COX-2 and 
EGFR in tumor tissue and correlate these with clinical-
epidemiological factors, and to evaluate their impact on 
the survival of patients with a diagnosis of gallbladder 
carcinoma, who underwent surgical resection at a tertiary-
level referral center for cancer treatment.
METHODS
A retrospective analysis was conducted on different 
prognostic factors presented by 42 patients who were 
treated at the “Francisco Morato de Oliveira” State of São 
Paulo Public Employees’ Hospital (Hospital do Servidor 
Público Estadual de São Paulo “Francisco Morato de 
Oliveira”, HSPE-FMO) with a histologically confirmed 
diagnosis of gallbladder adenocarcinoma. The period 
covered by this study was from January 1995 to January 
2006. This study was approved by the research ethics 
committees of HSPE-FMO, under the number 121/09, 
and the Federal University of São Paulo (UNIFESP) under 
the number 880/09. All the patients were respectively 
identified through the HSPE-FMO cancer register, and 
through this hospital’s pathology service.
Only the patients with adenocarcinoma were included 
in the sample, and all other histological subtypes were 
excluded. Only those who received surgical treatment 
were taken into consideration in the final analysis. Both 
the patients who underwent curative operations (R0) and 
those who underwent palliative operations (R1-R2) were 
included in this sample. Patients with metastatic disease 
were also excluded from this sample. All the information 
extracted using the protocol for constructing individual 
data files was used for identifying possible prognostic 
factors. This consisted of analysis on the following 
variables: 1) clinical data (age, sex and body mass index - 
BMI); 2) laboratory data (serum levels of albumin, bilirubins 
and the CA 19.9 and CEA tumor markers); 3) surgical data 
(type of operation, lymphadenectomy, perforation of the 
specimen and transfusion); 4) anatomopathological data 
(location, macroscopic type, incidental diagnosis, TNM 
stage, degree of differentiation, surgical margins (degree 
of radicalness), lymphatic or vascular embolization, 
perineural invasion, peri-tumoral inflammatory process 
and presence of necrosis); and 5) immunohistochemical 
data, i.e. the tumor tissue immunoexpression of the 
proteins P53, E-cadherin, COX-2 and EGFR. The seventh 
edition of the AJCC-TNM staging manual was used. 
Forty-two patients were identified and were used 
as the sample for this study. There were 35 women and 
seven men, with median age of 72 years (range: 34-87). 
Forty patients had white skin color and two had black skin 
color. The patients’ median BMI was 30 kg/m2 (range: 18-
38). The clinical variables studied are shown in Table 1.
TABLE 1 – Clinical variables 
Number of patients 42
Gender
     Male
     Female
7 
35
Age (years)  
     Median
     Range
72 
(34-87)
Skin color
     White
     Nonwhite
40
2
BMI (kg/m2)
     Median
     Range
30
(18-38)
ASA classification 
     ASA I
     ASA II
     ASA III
22
12
8
Clinical characteristics
     Biliary colic                                                                                                           
     Jaundice
     Acute cholecystitis
     Weight loss
     Acute cholangitis
     Acute pancreatitis 
14
13
12
5
3
2
Mode of presentation
     Incidental 
     Non-incidental
34
8
The albumin, bilirubin and tumor marker levels 
were assayed before the operation. The distribution of the 
laboratory serum assays is shown in Table 2.
TABLE 2 – Laboratory variables
Median (range) 
Bilirubins (ng/dl) 0,7 (0,2-28)
Albumin (ng/dl) 3,5 (1,3-4,7)
CEA (ng/dl) 4,5 (0,2-535)
CA 19.9 (ng/dl) 35,6 (1,2-24150)
All the patients in this series presented 
cholecystolithiasis and underwent cholecystectomy. 
In 37 cases, open surgery was used, while in five cases, 
a laparoscopic access route was used. In 15 patients, 
cholecystectomy was performed as an emergency 
procedure because of complications relating specifically 
to cholecystolithiasis, such as acute cholecystitis (n=12) 
or cholangitis (n=3). Nineteen patients presented 
gallbladder perforation: in fourteen cases, emergency 
operations were performed, while in five cases, elective 
cholecystectomy was performed. Twenty-three patients 
underwent complementary hepatectomy, in addition to 
cholecystectomy. In 20 of these, the hepatectomy consisted 
of removal of segments IVB and V, which in three cases, 
right hepatectomy expanded to segment IV was performed. 
Hepatectomy was performed in the same procedure 
as the cholecystectomy in eight patients (all with a 
preoperative diagnosis through imaging examinations). 
On the other hand, in 15 patients, it was performed as a 
second intervention, i.e. after the cholecystectomy, with a 
median time interval until the second intervention of 30 
days (range: 25-120). Among the 12 patients whose first 
operations were performed on an emergency basis due 
to acute cholecystitis, five underwent complementary 
hepatectomy and the other seven did not, because of 
postoperative death in one case, not being in a clinical 
condition for reintervention in four cases and refusing to 
undergo another surgical procedure in two cases. None 
of the three cases that were operated on an emergency 
basis due to cholangitis (comprising cholecystectomy with 
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Kehr drainage) because of failure of endoscopic treatment 
(CPRE) underwent subsequent hepatic resection because 
all of them died at the time of these emergency operations. 
Thirteen patients underwent not only hepatectomy but 
also resection of the main supra-pancreatic bile duct 
as far as the confluence of the hepatic ducts, together 
with construction of a biliodigestive anastomosis. The 
indications for bile duct resection were compromised 
margins of the cystic duct (n=8) or macroscopic invasion of 
the hepatic and common bile duct (n=2). In addition, one 
patient underwent right segmental colectomy and another 
underwent gastroenteric anastomosis.
Hilar lymphadenectomy was performed in 27 patients. 
Of these, 25 underwent operations with curative intent, 
while the other two were operated palliatively. The duration 
of the surgery ranged from 60 to 390 min, with a median of 
220 min. The surgical variables are demonstrated in Table 
3. The length of the hospital stay ranged from two to 45 
days, with a median of 15. Thirty-one patients received 
blood transfusions. Gallbladder perforation was observed 
in 19 patients during the operation. General postoperative 
complications were observed in 22 patients (morbidity 
of 52%), and eight patients required reoperation (20%). 
The commonest complication was biliary fistula (n=10), 
followed by pneumonia (n=9) and sepsis (n=7).  
TABLE 3 – Anatomopathological variables
Number of patients 42
Tumor grade
     I
     II/III
18
24
Tumor staging  
     T1
     T2
     T3
     T4
2
5 
31
4
Macroscopic characteristics
Lesion location:
     Fundus
     Neck
     Infundibulum
     Diffuse
29
0
8
5
Macroscopic type
     Papilliferous-fungoid     
     Nodular
     Infiltrative
     Ulcerated 
11
6
21
4
Microscopic characteristics
     Perineural invasion     
     Vascular embolization
     Lymphatic embolization
     Peri-tumoral inflammation 
     Necrosis 
     Perforation
27
26
26
13
23
19
Lymph nodes
     None
     N1
     Nx
17
19
6
The mortality rate during the immediate postoperative 
period (not more than one month after the operation) was 
12% (n=5). The causes of death were: infectious complications 
with sepsis (n=4) and acute myocardial infarction (n=1). 
Among these deaths, four patients had undergone emergency 
operations due to cholangitis (n=3) or acute cholecystitis 
(n=1), and none of these patients had undergone any type 
of hepatectomy. A single patient who underwent right 
hepatectomy on an elective basis died due to septic shock 
during the postoperative period because of a sequence of 
hemorrhage, hepatic abscess and reoperation. Only one 
patient in this series, who was staged as T3N1M0, underwent 
adjuvant chemotherapy (the last one in this sample).
The tumor was most frequently found in the fundic 
portion of the viscera (n=29) or in the infundibulum 
(n=8), or in a diffuse presentation (n=5). The commonest 
macroscopic type was schirrhous-infiltrative (n=21), 
followed by vegetative-exophytic (n=11), nodular (n=6) and 
infiltrative-ulcerated (n=4). In relation to the radicalness of 
the operations, based on the surgical margins, there was the 
following distribution: R0 (n=20), R1 (n=16) and R2 (n=6). 
The tumors that were operated were staged in accordance 
with the AJCC-TNM classification (7th edition, 2010), in 
relation to the degree of penetration of the organ wall and 
the lymph node involvement. The distribution in relation to 
T was as follows: T3 (n=31), T2 (n=5), T4 (n=4) and T1 (n=2). 
Nineteen patients presented compromised lymph nodes. In 
relation to the degree of cell differentiation of the tumors, 
the following distribution was observed: well differentiated 
(n=5), moderately differentiated (n=18) and poorly 
differentiated (n=19). The microscopic variables observed 
under the microscope (using HE) are shown in Table 4. 
TABLE 4 - Multivariate analysis: Cox proportional risks model
 p Odds Ratio CI 95% to Exp(B)
      Lower Upper
Albumin (< 3 ng/dl) 0,006 21,943 2,472 1947,51
Bladder perforation 0,000 20,712 3,864 111,010
Necrosis  0,000 20,712 3,864 111,010
EGFR immunoexpression 0,000 8,903 2,653 29,875
Four biomarkers (the human monoclonal antibodies 
P53, E-cadherin, COX-2 and EGFR) were used for 
immunohistochemical analysis by means of the streptavidin-
biotin-peroxidase technique. Anti-P53 (clone DO-7, Dako 
Corporation, Denmark) and anti-E-cadherin (clone NCL E-Cad 
P, Novocastra Corporation, Denmark) were both used at the 
dilution of 1:40. Anti-COX-2 (clone CX-294, Dako Corporation, 
Denmark) and anti-EGFR (clone EP38Y, Dako Corporation, 
Denmark) were both used at the dilution of 1:1000. The first 
two analyses were performed in the pathology laboratory 
of the Federal University of São Paulo, and the other two 
were performed in the pathology laboratory of the Cancer 
Hospital of São Paulo (Hospital A.C. Camargo). In interpreting 
the immunohistochemical panel, positive findings of the 
antibodies investigated here were taken to be indicated by 
occurrences of a brown color in the cytoplasm area or cell 
nucleus. The positive control used consisted of histological 
slides that had previously been proven to be positive for these 
markers. The protein immunoexpression was evaluated in the 
tumor tissue and in normal mucosa obtained from the surgical 
margins adjacent to the tumor. The percentage of the cells 
that showed a positive reaction was evaluated (at 400x) and 
cells with doubtful staining and non-tumor cells were excluded 
from the evaluation of the markers. In the slides that were used 
as negative controls, the primary antibody of the reaction was 
subtracted. 
In evaluating the protein P53, the method recommended 
by Wee et al30 was used. In this, the intensity of the staining 
and the number of positive cells are considered. The intensity 
of the staining was assessed on a scale from 0 to 3, in which 
0 was a stain that was considered to be negative, 1 was weak 
staining, 2 was intermediate staining and 3 was strong staining. 
In relation to the number of positive cells, the assessment scale 
also went from 0 to 3, as follows: 0 represented the situation 
of no neoplastic cells showing staining, 1 was up to 10% of 
the cells, 2 was from 10 to 50% and 3 was more than 50%. 
The definitive score was given by the score for the intensity of 
the staining multiplied by the score for the number of stained 
cells. In this manner, the negative group (0) was defined when 
the product from multiplication was 0, products of 1 to 3 were 
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considered to be weakly positive (1+), products of 4 to 5 were 
moderately positive (2+) and products greater than or equal to 
6 were strongly positive (3+). 
In evaluating the protein E-cadherin, the method 
recommended by Zhang et al.29 was used. In this, the intensity of 
staining and the number of positive cells were also considered. 
The intensity of staining was on a scale from 0 to 3, such that 0 
was negative, 1 was weak staining, 2 was intermediate staining 
and 3 was strong staining. For the number of positive cells, the 
scale also ranged from 0 to 3, defined as follows: 0 represented 
a situation in which less than 5% of the neoplastic cells were 
stained, 1 was 5-25%, 2 was 26-50% and 3 was more than 50%. 
The definitive score was given by the score for the intensity 
of staining multiplied by the score for the number of stained 
cells. In this manner, the negative group (0) was defined when 
the product from multiplication was 0, products of 1 to 3 
were weakly positive (1+), products of 4 to 5 were moderately 
positive (2+) and products greater than or equal to 6 were 
strongly positive (3+). 
For evaluating the protein COX-2, the method 
recommended by Kim et al.10 was used. In this, only the 
intensity of staining was considered, on a scale from 0 to 3, 
such that 0 was considered to be negative, 1+ weak staining, 
2+ intermediate staining and 3+ strong staining. 
In evaluating the protein EGFR, the method was also 
based on the intensity of staining of the tumor cells, which 
was again divided into four categories, as described in the 
study by Kountarakis et al.12, on a staining scale from 0 to 3. 
The categories were as follows: 0 was negative, i.e. no marking 
or weak marking of less than 10% of the tumor cells; 1+ 
was marking of weak intensity, in some of the cytoplasm, in 
more than 10% of the cells; 2+ was complete marking of the 
cytoplasm, of weak to moderate intensity, in more than 10% of 
the cells; and 3+ was marking of strong intensity in more than 
10% of the cells (Figure 1). 
FIGURE 1 – Photomicrograph of neoplastic gallbladder 
mucosa with immunoexpression positive for 
the marker EGFR (immunohistochemistry, 100x)
In this manner, in relation to the immunohistochemistry 
findings, it was possible to assess the tissue immunoexpression 
of the protein P53 in 41 patients. The distribution according to 
the scores from 0 to 3 was as follows: 0+ =4 cases, 1+=10 cases, 
2+=6 cases and 3+=21 cases. The tissue immunoexpression of 
the protein E-cadherin could be assessed in 40 patients. The 
distribution according to the scores from 0 to 3 was as follows: 
0+=9 cases, 1+=15 cases, 2+=12 cases and 3+=4 cases. 
The tissue immunoexpression of the protein COX-2 could 
be assessed in 40 patients. The distribution according to the 
scores from 0 to 3 was as follows: 0+=9 cases, 1+=15 cases, 
2+=12 cases and 3+=4 cases. The tissue immunoexpression 
of the protein EGFR could be assessed in 39 patients. The 
distribution according to the scores from 0 to 3 was as follows: 
0+=19 cases, 1+=9 cases, 2+=7 cases and 3+=4 cases. 
To evaluate the overall survival, the time period 
considered was from the date of the operation to the time of 
death due to cancer or the last follow-up consultation. The 
outpatient follow-up was considered to be until the last return 
visit or death. The prognostic criteria were represented by the 
following parameters: recurrence, overall mortality, survival and 
disease-free length of time. Recurrences among the patients 
who had been operated with curative intent were ascertained 
by means of complementary examinations or laparotomy. 
For the statistical analysis, survival curves were estimated 
using the Kaplan-Meier method and were compared using the 
log-rank test. The Cox proportional risks model was used to 
determine the significant variables. Spearman’s nonparametric 
correlation test was used for analyses comparing the different 
variables. In the analyses, p-values<0.05 were taken to 
be statistically significant. All the statistical analyses were 
performed using the PASW statistical software, version 18 
(SPSS Inc., 2009). 
RESULTS
The overall mortality among the 42 patients with 
complete follow-up until the end of the study was 88% (n=37). 
One patient’s cause of death was unrelated to the disease 
(acute myocardial infarction after 13 months of follow-up). No 
cases were lost from the follow-up in the present sample. The 
survival rate was divided into monthly periods, in which the 
following distribution was observed: survival of up to three 
months (n=11); between four and six months (n=9); between 
seven and 12 months (n=12); between 13 and 24 months 
(n=4); and 25 months and over (n=8).
In relation to the disease-free length of time, the majority 
of the patients who underwent the operation evolved with 
recurrence (90%) and only four patients (10%) did not (the 
length of the follow-up ranged from 18 to 120 months). Among 
the patients who presented recurrence, the most frequent site 
was the peritoneum (n=12), followed by the liver (n=8). In 
seven patients, the recurrence was considered to be multiple. 
The mean length of follow-up among the patients was 
25.4 months (range: 1-120). In relation to the patients operated 
(R1), the mean follow-up was 36.4 months (range: 1-120). The 
overall median survival in this series was eight months, while 
the five-year overall survival estimated from the Kaplan-Meier 
curve, was 26.2% (Figure 2).
Analysis on prognostic factors 
Twenty-six variables were considered through univariate 
analysis as possible prognostic factors. Among these, only 
those that presented significance levels less than 0.1 were 
screened for multivariate analysis. The following variables were 
statistically significant in the univariate analysis: albumin, CEA, 
CA 19.9, radicalness, perforation of the specimen, transfusion, 
tumor location, T and N staging, degree of differentiation, 
presence of necrosis, lymphatic-vascular embolization, 
perineural invasion and immunoexpression of the proteins 
P53, E-CD and EGFR. However, from the multivariate analysis, 
only four variables remained as independent factors in relation 
to the final prognosis: serum albumin level, perforation of 
the specimen, necrosis and EGFR (Table 4). The Kaplan-Meier 
survival graph according to the different expressions of the 
protein EGFR is shown in Figure 2.    
Nonparametric correlation of the biomarkers 
In relation to the immunoexpression of the protein P53, 
direct correlations with the immunoexpression of EGFR (p=0.002) 
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and with the N staging (p=0.0011) were observed. In relation to 
the immunoexpression of the protein E-CD, direct correlations 
with the histological grade (p=0.015) and the schirrhous-
infiltrative histological pattern (p=0.03) were observed. On the 
other hand, in relation to the immunoexpression of the protein 
COX-2, direct correlations with high bilirubin levels (p=0.034), 
neoplasm located in the fundus of the bladder (p=0.012) 
and presence of necrosis (p=0.002) were observed. Finally, in 
relation to the immunoexpression of the protein EGFR, direct 
correlations with the serum levels of the tumor markers CEA 
(p=0.004) and CA 19.9 (p=0.016), and with T staging (p=0.016) 
and N staging (p=0.029), were observed.
FIGURE 2 – A) Overall survival curve (Kaplan-Meier) for full 
sample; and B) survival curve (Kaplan-Meier), 
according to the immunoexpression of EGFR
DISCUSSION
Since the first evaluation of P53 expression using 
immunohistochemistry in gallbladder carcinoma cases, 
which was published by Kamel et al.5 in 1993, there has 
been little study on this subject and the findings have been 
very variable. Moreover, there have been divergent results 
regarding correlations between this mutation and patients’ own 
prognoses1,2,23,25.
In a sample of 60 Brazilian patients, Rocha et al.25 found 
that 56.5% were positive, which was very close to the findings of 
the present study. According to these authors, positive findings 
of P53 immunoexpression have ranged from 36.9 to 95%. The 
variations between different samples may be explained by specific 
situations such as the type of antibody used, the study sample 
and the classification method. Cases that are more advanced 
tend to have higher rates of positive findings than do early 
findings, thus suggesting that immunoexpression of the protein 
P53 in gallbladder carcinoma cases is associated with a late event 
in carcinogenesis23. In a sample of 191 cases, in which 45% of 
the sample expressed P53, Roa et al.23 observed that there was 
higher frequency of expression in advanced lesions (n=122) than 
in early lesions (n=22). However, because of the small sample of 
early lesions, they were unable to affirm the correlation with any 
certainty. The fact that higher immunoexpression occurs in more 
advanced cases may suggest, as observed in the present sample, 
that there is greater correlation with N staging (as observed 
through Spearman’s nonparametric correlation), in which the 
variable N was associated with positive P53 immunoexpression. 
This finding can perhaps be correlated with T3 or T4 staging, 
given that these cases formed the absolute majority of the 
present sample and are known to present a greater degree of 
lymph node involvement than T2 or T1 tumors. 
In the final prognostic assessment of survival, was 
only found a prognostic correlation of P53 expression in the 
univariate analysis; this association was not maintained in the 
multivariate analysis. Likewise, neither Rocha et al.25 nor Ajiki 
et al.1 found any final correlation with survival, although, again 
like the present study, these series were mostly composed of 
advanced cases. Nonetheless, Roa et al.23 did find a prognostic 
correlation with positive immunoexpression of P53. Thus, new 
studies should be conducted in order to attempt to identify 
whether P53 expression is or is not associated with the final 
prognosis in gallbladder carcinoma cases, independent of 
whether they might be associated with more advanced stages 
such as T3, T4 or N+.   
In the present sample, there was a direct relationship, using 
Spearman’s correlation, between the immunoexpression of the 
protein P53 and that of the protein EGFR. This association remains 
poorly understood, although some in vitro studies have shown 
that the P53 tumor-suppressing gene has an important role in 
controlling tumor angiogenesis17. Since high P53 expression may 
be associated with more advanced stages and with aggressive 
biological behavior, there is perhaps a greater tendency towards 
tumors with a profile of higher expression of EGFR, given that 
this protein is important with regard to greater local invasion 
and metastatic transformation. However, this association has 
not been observed in gallbladder carcinoma cases. On the other 
hand, in papilliferous thyroid carcinomas, Chen et al.3 observed 
a correlation between the immunoexpression of the protein 
P53 and that of EGFR, i.e. there was co-overexpression that also 
coincided with the presence of compromised lymph nodes, 
tumor size and more advanced staging. 
Also in the present study, there was a correlation between 
the protein P53 and lymph node involvement. Although Ajiki 
et al.1 did not find any correlation between P53 expression and 
dissemination in lymph nodes, a more recent study by Shu et al.27 
also found a correlation between P53 expression in gallbladder 
carcinoma cases and lymph node metastases. However, contrary 
to what was observed in the present study, the latter authors 
also observed a correlation between positive expression and 
worse final prognosis.    
Cadherins form part of the adhesion molecules that are 
fundamental to the processes of tissue invasion and metastatic 
transformation. There is little information about the prognostic 
implications of E-CD in relation to gallbladder carcinoma. In a 
sample of 139 patients with gallbladder carcinoma, Chang et al.2 
found high expression of E-CD in 96 patients and a difference in 
median survival of 14 months between patients with and without 
expression of this protein. In our multivariate analysis, high 
expression of E-cadherin was an independent protection factor 
(p=0.009). In addition, in making nonparametric correlations, 
there was an association with the histological grade and the M 
and T staging. In other words, the lower the tissue expression of 
E-cadherin was, the greater the proportions of undifferentiated 
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tumors, metastases (M) and thickness of invasion of the viscera 
(T) were. However, no prognostic correlation between E-CD 
expression and survival was found in the present study, just as 
in Roa et al.24. There was a prognostic correlation only in the 
univariate analysis, and this was not maintained in the univariate 
analysis possibly because of the sample size. On the other hand, 
there was an association between E-cadherin expression and the 
histological grade and schirrhous-infiltrative pattern. 
Current evidence suggests that increased prostaglandin 
levels through overexpression of COX-2 has been found in the 
growth of different types of human neoplasia of the digestive 
tract, such as carcinomas of the colon, stomach, esophagus 
and, more poorly recognized, the gallbladder10. In a Korean 
sample of 67 cases of gallbladder carcinoma, Kim et al.11 
observed associations between overexpression of COX-2 and 
both overall survival and disease-free survival. These authors 
also found correlations with factors that are known to have a 
poor prognosis, such as vascular invasion (p<0.011), lymphatic 
invasion (p<0.001), perineural invasion (p<0.001), TNM staging 
(p=0.001) and non-papilliferous morphology (p=0.003). Like in 
the sample of 56 cases of gallbladder carcinoma described by 
Legan et al.14, no association with overall survival was observed 
in the present study. In those authors’ sample, 29 patients (51%) 
presented immunoexpression positive for COX-2. The median 
survival observed among the patients with positive expression 
was 10.5 months, versus 18.3 months among those with negative 
expression (p=0.06). In the present study, 16 patients (40%) had 
positive immunoexpression and there was no association with 
survival (p=0.289). However, this variable was associated with the 
presence of necrosis and with tumors with fundic location in the 
bladder. Although we did not find reports of these associations 
in the literature, there is a logical association in relation to 
necrosis, given that COX-2 expression has been correlated with 
markers for angiogenesis and vascular neoformation, along with 
tissue hypoxia, which may be associated with necrosis. 
EGFR and HER2 are tyrosine kinase receptors encoded by 
proto-oncogenes. Growth factors such as the epidermal growth 
factor bind to these receptors in their extracellular binding 
domain and start cascades of intracellular signaling that lead 
to tumor cell proliferation, migration, invasion, resistance to 
apoptosis and angiogenesis. In a model for experimental cancer 
development with a high proportion of ErbB-2(HER2), the 
transgenic rats that were used developed gallbladder carcinoma, 
which suggests that ErbB-2 has a signaling role in gallbladder 
carcinogenesis17,28.
In a general manner, overexpression of EGFR and HER2 
in tumor cells has been correlated with poor prognosis. 
However, in parallel, this offers a therapeutic option known as 
targeted therapy, using specific medications that target these 
receptors15,21. So far, few studies have evaluated overexpression 
of EGFR in gallbladder carcinoma cases, and the rates of positive 
findings from immunohistochemistry have ranged from 16 to 
100%4,6,8,13,15,21,26. The overexpression rate (2+ and 3+) of 28% in 
the present sample was close to what was found by Hader et al.4 
and Pignhochino et al. 21, and accounted for around one third of 
the whole sample.  
In 1995, Lee & Pirdas13 were the first to describe an 
association between the membrane receptor EGFR and 
cases of gall bladder carcinoma and other bile duct tumors, 
and its correlation with gallbladder dysplasia and chronic 
calculous cholecystitis. In their study, 100% overexpression was 
demonstrated in a small sample of 13 patients, which led to 
the hypothesis of this possible correlation. According to Leone 
et al.15, chronic biliary inflammation and cholestasis lead to 
production of cytokines and free radicals, which in turn causes 
cell lesions and irreversible damage to DNA. This process leads 
to malignant transformation of cholangiocytes. Furthermore, 
presence of biliary acids in cases of chronic cholestasis 
functionally activates the EGFR cascade via transformation of the 
alpha growth factor, thereby leading to activation of the paths 
that promote cell survival, cell proliferation and inhibition of 
apoptosis. These are the most important characteristic processes 
of cholangiocarcinogenesis. All the indications are that there 
is a close relationship between overexpression of EGFR and 
carcinogenesis in gallbladder carcinoma cases.
In a Japanese sample of 77 gallbladder carcinoma cases, 
Kawamoto et al.8 observed high expression in 16%, which led to 
the belief that differences between particular samples probably 
occur because of regional, epidemiological, reagent use or 
classification differences between the groups. Subsequently, 
in a small American sample of 16 patients, Kaufman et al.6 
observed that 75% presented overexpression, all graded as 
3+ and presented as undifferentiated tumors. On the other 
hand, in patients with immunoexpression graded as 1+, there 
was a greater number of differentiated tumors. The patients 
with greater expression of EGFR presented shorter survival, 
which suggested that the prognosis was worse, although this 
conclusion was not entirely valid because of the small sample 
size. Recently, Sergeant et al.26 evaluated different biomarkers for 
hypoxia (VEGF, HIF1alpha, GLUT1, GLUT3, CA9 and EGFR) in 34 
patients with gallbladder carcinoma and showed that there was 
high expression in half of these cases. High expression of EGFR 
was correlated in multivariate analysis with low overall survival 
and was considered to be an independent variable (p=0.04). 
Patients with high levels of EGFR expression (>50%) presented 
median survival of only 3.7 months, versus 15.8 months for those 
with immunoexpression less than 50%. The risk of death among 
patients with EGFR overexpression was 2.5 times higher than in 
the control group (odds ratio=2.50; CI=1.04-6.07). These data 
were similar to what was found in the present study, in which 
there were differences in survival between the groups with high 
expression (survival of four months for 2+ and three months 
for 3+) and the group without immunoexpression for EGFR (18 
months) or the group with a score of 1+ (14 months). The odds 
ratio for death among the patients with high expression of EGFR 
was around nine times greater than among those with weak or 
no expression. 
In the present study, Spearman’s test showed a 
nonparametric correlation between high EGFR expression and 
the preoperative levels of the serum markers CA 19.9 and CEA, 
and also tumors with more advanced staging in the TNM-UICC 
classification. In relation to the serum markers CA 19.9 and CEA, 
this association had not previously been observed in gallbladder 
carcinoma cases. The correlation between EGFR and the TNM 
staging in gallbladder carcinoma cases had not been reported in 
the literature, although this association had been well described 
in other tumors of the digestive tract, such as colorectal16 and 
esophageal19 tumors.     
In summary, a prognostic correlation with 
immunoexpression of the protein EGFR was observed, which 
signals that further studies should be conducted in order to 
evaluate this association better. If this association were to be 
confirmed, it would create a justification for routinely including 
it in the prognostic assessment of gallbladder carcinoma and, 
perhaps, would lead to indication of use of anti-EGFR therapy 
(targeted therapy).    
CONCLUSION
Worse prognosis was related to increased immunoexpression 
of the protein EGFR in the tumor tissue.
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